Based on funding availability, a limited number of Merit Awards will be awarded to fellows/oncology trainees whose research is addressed in high-quality abstracts submitted to an ASCO Meeting and recognized for its scientific merit.

Merit Award recipients are honored with the opportunity to present their abstract at the Meeting, receive $1,000 in monetary support, complimentary registration for the Meeting, and access to reserved Meeting hotel reservation blocks. Merit Award candidates must apply for this award at the time of abstract submission.

For the ASCO Annual Meeting Merit Awards, Conquer Cancer has dedicated funds for the following areas and groups: breast cancer, gastrointestinal cancer, geriatric oncology, genitourinary cancer, lung cancer, female lung cancer researchers and researchers from Florida and outside the United States. Abstracts in other types of oncology-related research are also highly encouraged.


Applicants must meet the following criteria to be considered for a Merit Award:

  • Be the First Author on the abstract submission and agree to present the abstract if selected for presentation at the Meeting

  • Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD)
  • Be enrolled in an oncology fellowship training program, a radiation oncology residency program, or an equivalent oncology training program at the time of abstract submission
  • Work in an oncology laboratory or clinical research setting
  • Provide a letter of support from their training program director, indicating eligibility for the award
  • Provide a curriculum vitae

Special Merit Awards

Special Merit Awards are presented each year to trainees and junior faculty who have the top-ranking abstracts for the ASCO Annual Meeting. In addition to the stipend, recipients receive a plaque and are recognized at the ASCO Annual Meeting.

Bradley Stuart Beller Endowed Merit Award ($2,000)

This award is given to the fellow who has the highest ranking abstract overall in the Merit Award category as determined by the Scientific Program Committee.

Brigid Leventhal Special Merit Award ($1000)

This award is given to the fellow who submitted the top abstract in Pediatric Oncology as determined by the Scientific Program Committee.

Pain and Symptom Management Special Merit Award ($1000)

This award is given to the fellow who submitted the top abstract in Pain and Symptom Management Research as determined by the Scientific Program Committee.

Allen S. Lichter, MD Endowed Merit Award ($1000)

This award is given to the fellow who has the second highest ranking abstract in the Merit Award category as determined by the Scientific Program Committee.

James B. Nachman Endowed ASCO Junior Faculty Award in Pediatric Oncology ($3,000)

This award was established in memory of James B. Nachman, MD, Professor of Pediatrics at the University of Chicago and an internationally renowned pediatric cancer expert. It is endowed through the James B. Nachman Pediatric Oncology Fund and will be given each year to a junior faculty member who submits the highest ranking abstract in pediatric oncology for the ASCO Annual Meeting as determined by the ASCO Scientific Program Committee. The recipient will receive $3,000 in monetary support to attend the Annual Meeting, complimentary registration for the Annual meeting and access to reserved Meeting housing. Candidates must apply for this award at the time of abstract submission.

The First Author must meet all of the following requirements to be considered for the James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology:

  • Hold a medical or doctoral degree (MD, PhD, DO, or DNP)
  • Be within 7 years of their first faculty appointment at the time of abstract submission
  • Conduct laboratory, population-based, or clinical research focused on childhood cancer
  • Agree to present the abstract at the ASCO Annual Meeting
  • In addition, the abstract must be selected for presentation in an Oral Abstract Session

Application Instructions

Consideration for a Merit Award is available on the abstract submitter for the ASCO Annual Meeting and other ASCO thematic meetings.

Abstract Submission Deadlines:

  • 2018 Palliative and Supportive Care in Oncology Symposium: July 24, 2018, at 11:59 PM EDT
  • 2019 Gastrointestinal Cancers Symposium: September 25, 2018, at 11:59 PM EDT
  • 2019 Genitourinary Cancers Symposium: October 23, 2018, at 11:59 PM EDT
  • 2019 ASCO-SITC Clinical Immuno-Oncology Symposium: November 6, 2018 at 11:59 PM EST
  • 2019 ASCO Annual Meeting: February 12, 2019 at 11:59 PM EST

For Merit Award eligibility and application questions, please contact

2018 Annual Meeting Merit Award Recipients

Jithma Abeykoon, MD
Mayo Clinic, Rochester
Daratumumab-based therapies in patients with AL amyloidosis.
Kathryn Arbour, MD
Memorial Sloan Kettering Cancer Center
Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.
Rita Assi, MD
The University of Texas M.D. Anderson Cancer Center
Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML).
Romualdo Barroso-Sousa, MD, PhD
Dana-Farber Cancer Institute
Determinants of high tumor mutational burden (TMB) and mutational signatures in breast cancer.
Francesca Battaglin, MD
University of South Carolina
Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): data from TRIBE and FIRE-3 phase III trials.
Manali Bhave, MD, BA
Northwestern University
A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).
Prajwal Boddu, MD
The University of Texas M.D. Anderson Cancer Center
Validation of the ELN-2017 Risk Classification in Younger Adult Patients (pts) with AML.
Joseph Bodor, MD, PhD
Fox Chase Cancer Center
Pathogenic somatic mutation (SM) of mismatch repair (MMR) genes and associations with microsatellite instability (MSI), tumor mutational burden (TMB) and SM in other DNA repair pathways in 24,223 tumor genomic profiles.
Dominick Bossé, MD, MSc
Dana-Farber Cancer Institute
Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
Elena Braicu, MD, PhD
Charité University Hospital, Germany
Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC).
Yanshuo Cao, MD
Princess Margaret Cancer Centre, Canada
Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions.
Luisa Carbognin, MD
University of Verona
Next-Generation Targeted Sequencing (NGTS) investigating CDK4 as a prognostic driver in pure Invasive Lobular Breast Carcinoma (ILC): preliminary results in early-stage patients (pts) stratified according to a validated clinico-pathological model.
Alessia Castellino, MD
Mayo Clinic, Rochester
Title: Long term follow-up (FU) of lenalidomide plus R-CHOP therapy in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): combined analysis from two phase 2 trials.
Fernando Caumont, MD
Virginia Mason Medical Center
Primary Testicular Lymphoma: Treatment Patterns and Survival of 1740 Men From the National Cancer Database.
Fumiko Chino, MD, BA
Duke University
Trends and disparities in place of death for cancer patients in the United States, 1999-2015.
Kevin Chua, MBBS
National Cancer Centre Singapore
Dependency of radiotherapy and combinatorial radio-immunotherapy responses on the systemic t cell immune response.
Katherine Clifton, MD
The University of Texas M.D. Anderson Cancer Center
Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.
Julie Collins, MD, MPH
National Cancer Institute
Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.
Vincenza Conteduca, MD, PhD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Italy
Plasma androgen receptor (pAR) status and activity of taxanes in metastatic castration resistant prostate cancer (mCRPC).
Colleen Cuthbert, PhD
University of Calgary, Canada
Effect of comorbidities on outcomes in colorectal cancer (CRC) survivors.
Ila Datar, PhD
Yale University
Expression and clinical significance of antigen presentation components beta-2 microglobulin, HLA class I heavy chains, and HLA class II in non-small cell lung cancer (NSCLC).
Lisa Derosa, MD
Institut Gustave Roussy, France
Gut microbiome composition predicts resistance in renal cell carcinoma (RCC) patients on nivolumab.
Arpita Desai, MD
University of Chicago
Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
Michael Devitt, MD
University of Virginia
Risk of CNS adverse events (CNS-AEs) for patients with non-small cell lung cancer (NSCLC) and melanoma brain metastases (BM) treated with CNS radiation (CNS-RT) and immune checkpoint inhibitors (CPIs).
Bhagirathbhai Dholaria, MBBS
H. Lee Moffitt Cancer Center & Research Institute
Efficacy of up-front hematopoietic cell transplantation in peripheral t-cell lymphoma, not otherwise specified (PTCL-NOS): A National Cancer Database analysis.
Stephanie Dixon, MD, BS
St. Jude Children's Research Hospital
Racial/Ethnic Differences in Neurocognitive, Emotional and Quality of Life Outcomes in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS).
Soniya Dulal, MD
National Academy of Medical Sciences, Bir Hospital, Nepal
Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.
Gustavo Fernandes, MD
Memorial Sloan Kettering Cancer Center
Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC).
Ahmad Ghorab, MD, MSc
The University of Texas M.D. Anderson Cancer Center
Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation.
Ragisha Gopalakrishnan, MD, BS
Vanderbilt University
Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).
Kyle Greene, MD
University of Utah
Multi-center Retrospective Study Evaluating Outcomes of Grade 3A Follicular Lymphoma (FL).
Shuchi Gulati, MD, FACP
University of Cincinnati
A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma.
Pat Gulhati, MD, PhD
The University of Texas M.D. Anderson Cancer Center
Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.
Anis Hamid, MBBS
Dana-Farber Cancer Institute
Clinical outcomes with cumulative tumor suppressor gene (TSG) alterations in castration sensitive (CSPC) and resistant (CRPC) prostate cancer.
Simon Heidegger, MD
Technical University of Munich, Germany
Melanoma cell-intrinsic RIG-I but not STING signaling is required for checkpoint inhibitor‑mediated anticancer immunity.
Brian Henick, MD
Yale School of Medicine
Multiplexed analysis of myeloid cell (MC) markers to characterize the innate immune composition and clinical features of human non-small cell lung carcinomas (NSCLC).
Raul Herrera, MD
The University of Texas M.D. Anderson Cancer Center
Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab.
Amy Houghtelin, MD, BS
Children's National Medical Center
Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors.
Boyu Hu, MD
The University of Texas M.D. Anderson Cancer Center
ATM mutation and unmutated IGHV status are independently associated with shorter time to first treatment (TTFT): An analysis of multigene mutation profiling and standard prognostic clinical markers in 384 treatment-naive (TN) chronic lymphocytic leukemia (CLL).
Megan Jagosky, MD
Levine Cancer Institute
Molecular analyses of left- and right-sided tumors in adolescents and young adults (AYA) with colorectal cancer (CRC).
Anuradha Jayaram, MBBS, MRCP
Institute of Cancer Research and The Royal Marsden NHS Trust Foundation
Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone (+P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).
Elizabeth Jimenez Aguilar, MD
Dana-Farber Cancer Institute
Comparison of outcomes with PD-L1 tumor proportion score (TPS) of 50-74% vs 75-100% in patients with non-small cell lung cancer (NSCLC) treated with first-line PD-1 inhibitors.
Archit Joshi, MD
Cancer Institute (WIA)
Intravenous fosaprepitant for the prevention of chemotherapy induced vomiting in children: A double blind placebo controlled, phase III randomized trial.
Jin Kang, MD
Guangdong Lung Cancer Institute, China
Uncommon ALK fusion partners in advanced ALK-positive non-small-cell lung cancer.
Yada Kanjanapan, MBBS
Princess Margaret Cancer Centre, Canada
Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.
Tyler Ketterl, MD
Fred Hutchinson Cancer Research Center
Impact of cancer on employment and finances in young adult (YA) survivors.
Daniel Khalaf, MD
British Columbia Cancer Agency, Canada
Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): results for 2nd-line therapy.
Lillian Klug, PhD
Portland VA Health Care System and OHSU Knight Cancer Institute
LMTK3 regulates the translation of oncogenic KIT in GIST regardless of imatinib sensitivity.
Michael Lam, MBBS
The University of Texas M.D. Anderson Cancer Center
Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.
Matteo Lambertini, MD
Institut Jules Bordet, Belgium
Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
Nathalie LeVasseur, MD
British Columbia Cancer Agency, Canada
Whole Genome Sequencing in Metastatic Breast Cancer – Lessons Learned from the BC Cancer Personalized Oncogenomics Program.
Bryan Li, MD
The Hospital for Sick Children, Canada
Genomic landscape of pineoblastoma.
Wenhua Liang, MD
First Affiliated Hospital of Guangzhou Medical University, China
Association between certain NSCLC driver mutations and sensitivity markers for chemotherapy or PD-(L)1 inhibition: A large-sample analysis.
Kristina Lindemann, MD, PhD
University of Oslo
End of life care in gynaecological cancer patients: A population-based study of cancer deaths from the Swedish Register of Palliative Care.
Shiru Liu, MD
British Columbia Cancer Agency, Canada
Adjuvant chemotherapy and survival outcomes in diabetic patients with colon cancer: A population-based analysis.
Stephen Luen, MBChB
Peter MacCallum Cancer Centre, Australia
Prognostic implications of residual disease (RD) tumor-infiltrating lymphocytes (TIL) in triple negative breast cancer (TNBC) after neo-adjuvant chemotherapy (NAC).
Eoghan Malone, MB BCh, BAO, BA, MSc, MRCPI
Princess Margaret Cancer Centre, Canada
Phase 1b study of selinexor, a first in class Selective Inhibitor of Nuclear Export (SINE) compound, in combination with doxorubicin in patients (pts) with locally advanced or metastatic soft tissue sarcoma (STS).
Shearwood McClelland, MD
Oregon Health and Science University
Long-term stroke risk of single-fraction photon-based stereotactic radiosurgery for meningioma.
Kathan Mehta, MBBS, MPH
University of Pittsburgh
Overall Survival Based on Oncologist Density in the United States; Do We Need to Redefine Underserved Areas for Oncologic Care?
Aaron Mitchell, MD
The University of North Carolina at Chapel Hill
Duration of physician-industry relationships and prescribing changes in oncology.
Karmanos Cancer Institute
Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.
Kevin Nead, MD, MPhil
University of Pennsylvania
Risk of pediatric malignancy in families known to carry BRCA1/2 mutations.
Tomohiro Nishijima, MD
New York University
The value of inflammatory markers in predicting overall survival in older adults with cancer.
Maliha Nusrat, MD
The University of Texas M.D. Anderson Cancer Center
Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.
Michael Offin, MD
Memorial Sloan Kettering Cancer Center
Tumor Mutation Burden and Efficacy of Targeted Therapy in Patients with EGFR Mutant Lung Cancers.
Marc Oliva, MD
Princess Margaret Cancer Centre, Canada
Cisplatin dose intensity (CDDP-D) in human papillomavirus-positive (HPV+) localized oropharyngeal carcinoma (OPC) treated with chemoradiotherapy (CRT).
Thomas Ollila, MD
Brown University
Radiation Therapy in Primary Testicular Lymphoma (PTL): Does Practice Match the Standard of Care?
Daniel Olson, MD
The University of Chicago
Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).
Seyed Pairawan, MD
The University of Texas M.D. Anderson Cancer Center
Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer.
Kaushal Parikh, MD
New York Medical College
A nationwide analysis of palliative care service utilization in hospitalized metastatic cancer patients.
Wungki Park, MD
University of Miami, Miller School of Medicine
Predicting outcomes of advanced non-small cell lung cancer patients treated with PD-1/PDL-1 inhibitors: independent international validation of the iSEND model.
Christine Parseghian, MD
The University of Texas M.D. Anderson Cancer Center
Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.
Sandro Pasquali, MD
Fondazione IRCCS- Istituto Nazionale dei Tumori, Italy
Allan Pereira, MD, PhD
The University of Texas M.D. Anderson Cancer Center
Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).
Noam Ponde, MD
Centro Paulista de Oncologia
An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.
Alberto Puccini, MD
University of South Carolina
Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Chethan Ramamurthy, BA, MD
Fox Chase Cancer Center
Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).
Rahul Ravilla, MD
University of Arkansas
Cervical microbiome role in outcomes of therapeutic HPV vaccination for cervical intraepithelial neoplasia.
Pasquale Rescigno, MD
The Royal Marsden Hospital, The Institute for Cancer Research, United Kingdom
Molecular and clinical implications of CHD1 loss and SPOP mutations in advanced prostate cancer.
Nuria Romero-Laorden, MD, PhD
Hospital Universitario La Princesa
Impact of treatment sequence on the outcomes of metastatic castration resistant prostate cancer patients (mCRPC) with germline BRCA2 mutations: A subanalysis of the PROREPAIR-B study.
Daniele Rossini, MD
Azienda Ospedaliera Universitaria Pisana, Istituto Toscano Tumori
Liquid biopsy allows predicting benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to 1st-line cet+iri: final results and translational analyses of the CRICKET study by GONO.
Joshua Sabari, MD
Memorial Sloan Kettering Cancer Center
RET-Rearranged Lung Cancers: Immunophenotype and Response to Immunotherapy.
Andreas Saltos, MD
H. Lee Moffitt Cancer Center & Research Institute
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
Stephen Schleicher, MD, MBA
Memorial Sloan Kettering Cancer Center
Cancer survival in the context of growing hospital participation in Medicare ACOs.
Shiraj Sen, MD, PhD
The University of Texas, Southwestern
Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials.
Adam Sharp, MD, PhD
The Royal Marsden Hospital, The Institute for Cancer Research, United Kingdom
The Prognostic and Predictive Value of AR-V7 Quantification in mCRPC.
Takehito Shukuya, MD
The Ohio State University
Circulating miRNA and extracellular vesicle containing miRNA as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.
Tharani Sivakumaran, MD
Peter MacCallum Cancer Centre, Australia
Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.
Hadas Sorotsky, MD
Princess Margaret Cancer Centre, Canada
The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).
Paolo Strati, MD
The University of Texas M.D. Anderson Cancer Center
Achievement of complete remission (CR) is a desirable endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib.
Stephanie Sullivan, MD
University of North Carolina, Chapel Hill
Genomic profiling of lymph node metastases in endometrial cancer and association with volume of metastasis.
Roger Sun, MD, PhDc
Institut Gustave Roussy, France
Medical image computing to assess tumor infiltrating CD8 T cells, tumor immune phenotype and response to anti-PD-1/PD-L1 immunotherapy in prospective phase 1 trials.
Mahesh Swaminathan, MBBS
The University of Texas M.D. Anderson Cancer Center
Early intervention in transfusion independent (TI) patients (Pts) with lower-risk myelodysplastic syndromes (MDS) treated with attenuated doses of hypomethylating agents (HMAs) is associated with high response rates and long duration of response.
Nina Tamirisa, MD, MS
Duke University
The Impact of Chemotherapy Sequence on Survival in Node-Positive Invasive Lobular Carcinoma.
Aaron Tan, MBBS, PhD, BSc
Royal North Shore Hospital
Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).
Jessica Tao, MD, BS
Memorial Sloan Kettering Cancer Center
PRECISE: A clinical-grade automated molecular eligibility screening and just-in-time (JIT) physician decision support solution for molecularly-selected oncology trials.
Vatche Tchekmedyian, MD
Memorial Sloan Kettering Cancer Center
A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
Sibo Tian, MD
Emory University
Survival Outcomes by HPV Status in Non-Oropharyngeal Head and Neck Cancers: A Propensity Score Matched Analysis of Population Level Data.
Nadina Tinsley, MBBS, MRCP
The Christie NHS Foundation Trust, United Kingdom
Cumulative antibiotic use significantly decreases efficacy of immune checkpoint inhibitors in patients with advanced cancer.
Ryuma Tokunaga, MD, PhD
University of South Carolina
Molecular characterization of appendiceal cancer and comparison with right-sided (R-CRC) and left-sided colorectal cancer (L-CRC).
Mehdi Touat, MD
Dana-Farber Cancer Institute
ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.
Veerisa Vimolchalao, MD
Chulalongkorn University
Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.
Panagiotis Vlachostergios, MD, PhD
Weill Cornell Medical College & New York-Presbyterian Hospital
Upper tract urothelial carcinoma is non-basal and T-cell depleted.
Natalie Vokes, MD, MPhil
Dana-Farber Cancer Institute
Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.
Adrienne Waks, MD
Dana-Farber Cancer Institute
The tumor-immune microenvironment (TME) in HR+/HER2- metastatic breast cancer (mBC): relationship to non-metastatic (met) tumors and prior treatment (tx) received.
Seth Wander, MD, PhD, BS
Dana-Farber Cancer Institute
Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).
Jennifer Wang, MD, ScM
The University of Texas M.D. Anderson Cancer Center
Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival.
Kunning Wang, PhD
Xi'an Jiaotong University
Differential response to adjuvant chemotherapy based on Lauren subtype affects clinical outcome of gastric cancer: A cohort study and meta-analysis.
Yucai Wang, MD, PhD
Mayo Clinic, Rochester
Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
Patrick Williams, MD, PhD
University of Texas M.D. Anderson Cancer Center
Treg infiltration and the expression of immune checkpoints associated with T cell exhaustion in AML.
Juliet Wolford, MD
University of California, Irvine
Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.
Xiaoliang Wu, MD
West Virginia University
Mass spectrometry biomolecular omics profiling and imaging to dissect the initial emergence of molecular drug resistance in ALK-positive (ALK+) lung cancer.
Fevzi Yalniz, MD
The University of Texas M.D. Anderson Cancer Center
Characteristics and outcomes of acute myeloid leukemia (AML) with extramedullary disease (EMD).
Divya Yerramilli, MD, MBBS
Harvard University
Cancer-related morbidity at the end of life in men with prostate cancer.
Todd Yezefski, MD, MS, BA
University of Washington
Comparison of chemotherapy use, cost, and survival in patients with metastatic colorectal cancer in Western Washington and British Columbia.
Steven Yip, MD
British Columbia Cancer Agency, Canada
Treatment Outcomes for Patients (Pts) with Metastatic Castration Resistant Prostate Cancer (mCRPC) Pts and DNA Damage Repair Gene Mutations.


The 2018 Merit Award is supported by:


Agios Pharmaceuticals, Inc.
ASCO Employees
Association of Northern California Oncologists
Friends and Family of Dr. and Mrs. Ronald Beller
The Berry Family
Dr. and Mrs. Douglas W. Blayney
Jonathan K. and Cora Y. Cho Charitable Fund
Estate of Darla C. Ellis
G1 Therapeutics
Dr. Arti Hurria and Dr. Hyman B. Muss
Ipsen Biopharmaceuticals Inc.
Michael Kelley, MD, & Elise Hoffman, PharmD
Kidney Cancer Association
Friends and Family of Dr. James B. Nachman
Northern New England Clinical Oncology Society
Dr. Kathleen Pritchard Medicine Professional
Frances A. Shepherd, MD, FASCO
Stephen A. Sherwin, MD
Drs. Rachna and Puneet Shroff
Nizar M. Tannir, MD
Dr. Michael and Deborah Troner

This list reflects commitments as of April 29, 2019.

This grant receives support that may result in a report to the CMS Open Payments website under the Physician Payments Sunshine Act. The supporting companies are required to report the amount of the grant, the names of physicians who are awarded this grant, and the names of their institutions. This information may appear on the Open Payments websiteFind out more information about the Sunshine Act and CMS Open Payments program.